Author Archives: Steve Walker

It’s time to reclassify schizophrenia as a neurologic disorder.

The News: A mental health advocacy group has spearheaded a new initiative to reclassify schizophrenia as a neurologic, rather than a psychiatric, disease. The action is designed to reduce stigma and ultimately… Read more »

Healthcare stocks keep rockin as February begins with searing action. Will it last, or flame out?

Winners far outpaced losers last week as the broader market continued to worry about trade talks with China and the prospect of another government shutdown over the Trump wall. Check… Read more »

Healthcare IPOs keep rolling along, and not just in the US. Will March come in like a lion, or a lamb?

The News: While markets take a breather during this holiday shortened week, any big IPO news in the US will likely come in the form of new filings. A company… Read more »

Three healthcare stocks shine while two fizzle to cap the first month of 2019’s investor lottery. Who’s a rational bet and who’s a pure gamble.

The healthcare stock market’s recent success is largely dependent on the fact that, as the global population increases and more people need access to healthcare, companies in the space are prepared… Read more »

IPOs are back in business; well, unless and until there’s another government shutdown.

IPOs are back in the race for torrents of cash. The government is fully funded until February 15, which means a wave of IPOs should begin launching today (Feb. 4)…. Read more »

And now for something completely different in biotech: Lab-grown, “clean” meat. If Bill Gates and Warren Buffett like the idea…well?

The Premise: Contemplate a world where eating meat derived from animals is a thing of the past. Ridiculous, you say. But during the past year, the field of cultured (or… Read more »

IPOs keep their hopes alive with new registrations

Unfazed by record government shutdown, 2019 healthcare IPOs burst out of the gate with 1 pricing and 5 filings. As expected, no IPOs priced this past week. And due to… Read more »

Spotlight on three winning stocks from the past week and one absolute washout. But buy the dud first, then see what we think about the others.

1) Axsome Therapeutics Inc. (Nasdaq:AXSM) led advancing issues, skyrocketing 180% last week to $7.36. On Jan. 7, the NYC-based company reported that its lead drug candidate, AXS-05, hit its primary endpoint in… Read more »